Since the stability of siRNA molecules inside the blood and efficiency of siRNA distribution into target organs or tissues subsequent systemic management are the main issues that limit requests of siRNA in human patients, we attempt to explore if siRNA liposome entrapment works within the development of novel therapeutics. Our study aims to guage the therapeutic effect of survivin siRNA nano particles, on cancer of the liver, carcinoma and cervical cancer both in vitro and in vivo. First, sequences of survive in siRNA we designed had been screened for his or her efficacy, and therefore the best one was chosen for subsequent study. Second, we've tested the biological effect of survivin siRNA nanoparticles on neoplastic cell lines in vitro, and resulted that, the survivin mRNA and its protein expression was significantly inhibited in MHCC-97H cells, HeLa cells and LoVo cells, also proliferation of these cell lines was inhibited and apoptosis was promoted. Third, subcutaneous xenograft Balb/c nude mice of MHCC-97H cells, HeLa cells or LoVo cells were established. Survivin siRNA nanoparticles (70.7±29.077nm in size), with dosage of 3 mg/kg survivin siRNA was given via local or injection, twice every week continuously for four weeks. As results, major tumor growth reserve both in local injection and venous injection was experiential, compared to regulate mice who received scribbled siRNA nan particles at an equivalent dosage, with inhibition rate of 32.22% and 36.67%, at the top of study in venous injection and native injection respectively, the relative tumor volume in mice with local injection showed significant but control group from 10 days after first injection (P<0.05) till 31 days, it had been also an equivalent situation in mice with venous injection compared to regulate, (P<0.05) except day 17, survivin mRNA and its protein were down regulated at the top of study, compared to regulate group. Our study also showed some inhibition activity of survivin siRNA nanoparticles in subcutaneous xenograft Balb/c nude mice of HeLa or LoVo cells, survivin mRNA and protein expression was all down regulated in tumor tissue compared to regulate. We considered the survivin siRNA with Cy3 florescence and injection to nude mice with MHCC-97H cells, and located intense Cy3 delivery in tumor mass, spleen and liver, but scant delivery in heart, bone marrow, brain, lung, and alimentary canal. Our study revealed that survivin siRNA nanoparticles were capable of inhibiting tumor growth both in vitro and in vivo.